Case Reports

Paraneoplastic Isaacs syndrome leading to diagnosis of small-cell lung cancer


 

Paraneoplastic Isaacs syndrome is a rare disorder with distinct clinical and electromyographic characteristics. It is a consequence of neoplastic process that is not directly caused by the tumor itself, but usually mediated by immune response primarily against the tumor and neural tissues are damaged owing to bystander effect. Paraneoplastic neurologic disorders may precede cancer diagnosis. Here we report the case of 75-year-old woman who presented with numbness, tingling sensation, and weakness of lower extremities, and was diagnosed with Isaacs syndrome and subsequently small-cell lung cancer. Plasmapheresis and treatment of small-cell lung cancer produced signficant symptoms improvement. We also conduct a complete review of the published case reports and case series of Isaacs syndrome of paraneoplastic etiology, which usually has good response to carbamazepine and to specfic treatment of underlying neoplasm.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

KRAS-targeted T-cell therapy derails metastatic cancer
MDedge Hematology and Oncology
Ganetespib fails to hit mark in phase III NSCLC trial
MDedge Hematology and Oncology
‘Vanishing’ role forecast for whole-brain irradiation for NSCLC metastases
MDedge Hematology and Oncology
VIDEO: Pivotal results nail osimertinib’s role in NSCLC
MDedge Hematology and Oncology
Pembrolizumab proves promising for treating advanced SCLC
MDedge Hematology and Oncology
Durvalumab could offer option for difficult-to-treat NSCLC
MDedge Hematology and Oncology
c-Myc could be key to alisertib potential in small-cell lung cancer
MDedge Hematology and Oncology
Toxicity high for SBRT in centrally-located lung tumors
MDedge Hematology and Oncology
VIDEO: Improved QOL an added benefit of pembrolizumab for NSCLC patients
MDedge Hematology and Oncology
Quality of life after surgery for pleural malignant mesothelioma – methodological considerations
MDedge Hematology and Oncology